Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21449037 | 0.89 | EPHX1 (0.41) | EPHX1KDM4CNPC1RAB9AMAPT | |
| SCHEMBL2824552 | 0.82 | BCHE (0.36) | EPHX1KDM4CSMN1; SMN2DRD2DRD3 | |
| SCHEMBL24535362 | 0.79 | CACNA1H (0.35) | TP53BP1 | |
| SCHEMBL21706216 | 0.78 | SIGMAR1 (0.41) | EPHX1KDM4CDRD2DRD3 | |
| SCHEMBL26309035 | 0.78 | KEAP1 (0.39) | EPHX1KDM4CNPC1RAB9AMAPT | |
| SCHEMBL8070563 | 0.78 | MEN1 (0.38) | EPHX1KDM4CMAPTDRD2DRD3 | |
| SCHEMBL11148743 | 0.77 | FAAH (0.37) | EPHX1KDM4CNPC1RAB9AMAPT | |
| SCHEMBL5540331 | 0.75 | PRMT1 (0.47) | KDM4C | |
| SCHEMBL8069886 | 0.73 | DNM1 (0.41) | EPHX1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22667281 | 0.73 | KDM4C (0.48) | EPHX1KDM4CNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190351066-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190351066-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | LGMN, BUB1B, KIF15 | EPHX1 3595/4885KDM4C 4363/4885NPC1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.